CoChat

Histone deacetylases modulate resistance to the therapy in lung cancer

Open access
Contreras-Sanzón, Estefanía, Prado-Garcia, Heriberto, Romero-Garcia, Susana, Nuñez-Corona, David, Ortiz-Quintero, Blanca, Luna-Rivero, Cesar, Martínez-Cruz, Victor, Carlos-Reyes, Ángeles · 2022 · Frontiers in Genetics
Cited by 38

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

The acetylation status of histones located in both oncogenes and tumor suppressor genes modulate cancer hallmarks. In lung cancer, changes in the acetylation status are associated with increased cell proliferation, tumor growth, migration, invasion, and metastasis. Histone deacetylases (HDACs) are a group of enzymes that take part in the elimination of acetyl groups from histones. Thus, HDACs regulate the acetylation status of histones. Although several therapies are available to treat lung cancer, many of these fail because of the development of tumor resistance. One mechanism of tumor resistance is the aberrant expression of HDACs. Specific anti-cancer therapies modulate HDACs expression, resulting in chromatin remodeling and epigenetic modification of the expression of a variety of genes. Thus, HDACs are promising therapeutic targets to improve the response to anti-cancer treatments. Besides, natural compounds such as phytochemicals have potent antioxidant and chemopreventive activities. Some of these compounds modulate the deregulated activity of HDACs (e.g. curcumin, apigenin, EGCG, resveratrol, and quercetin). These phytochemicals have been shown to inhibit some of the cancer hallmarks through HDAC modulation. The present review discusses the epigenetic mechanisms by which HDACs contribute to carcinogenesis and resistance of lung cancer cells to anticancer therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fgene.2022.960263

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Metadata

Authors
Contreras-Sanzón, E., Prado-Garcia, H., Romero-Garcia, S., Nuñez-Corona, D., Ortiz-Quintero, B., Luna-Rivero, C., Martínez-Cruz, V., & Carlos-Reyes, Á.
Venue
Frontiers in Genetics
Published
2022-10-03
Volume
13
Pages
960263-960263
ISSN
1664-8021 (ISSN-L)
OpenAlex
W4300961020
Cited by
38
References
9
FWCI
2.35
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Histone deacetylases modulate resistance to the therapy in lung cancer. https://app.cochat.ai/papers/10.3389/fgene.2022.960263
The paper
Contreras-Sanzón, E., Prado-Garcia, H., Romero-Garcia, S., Nuñez-Corona, D., Ortiz-Quintero, B., Luna-Rivero, C., Martínez-Cruz, V., & Carlos-Reyes, Á. (2022). Histone deacetylases modulate resistance to the therapy in lung cancer. Frontiers in Genetics. https://doi.org/10.3389/fgene.2022.960263

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.